204 related articles for article (PubMed ID: 36137524)
1. Swiss Recommendations for Cutaneous Basal Cell Carcinoma.
Ramelyte E; Nägeli MC; Hunger R; Merat R; Gaide O; Navarini AA; Cozzio A; Wagner NB; Maul LV; Dummer R
Dermatology; 2023; 239(1):122-131. PubMed ID: 36137524
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
Peris K; Fargnoli MC; Garbe C; Kaufmann R; Bastholt L; Seguin NB; Bataille V; Marmol VD; Dummer R; Harwood CA; Hauschild A; Höller C; Haedersdal M; Malvehy J; Middleton MR; Morton CA; Nagore E; Stratigos AJ; Szeimies RM; Tagliaferri L; Trakatelli M; Zalaudek I; Eggermont A; Grob JJ;
Eur J Cancer; 2019 Sep; 118():10-34. PubMed ID: 31288208
[TBL] [Abstract][Full Text] [Related]
3. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.
Peris K; Fargnoli MC; Kaufmann R; Arenberger P; Bastholt L; Seguin NB; Bataille V; Brochez L; Del Marmol V; Dummer R; Forsea AM; Gaudy-Marqueste C; Harwood CA; Hauschild A; Höller C; Kandolf L; Kellerners-Smeets NWJ; Lallas A; Leiter U; Malvehy J; Marinović B; Mijuskovic Z; Moreno-Ramirez D; Nagore E; Nathan P; Stratigos AJ; Stockfleth E; Tagliaferri L; Trakatelli M; Vieira R; Zalaudek I; Garbe C;
Eur J Cancer; 2023 Oct; 192():113254. PubMed ID: 37604067
[TBL] [Abstract][Full Text] [Related]
4. The current clinical approach to difficult-to-treat basal cell carcinomas.
Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for inoperable and metastatic basal cell cancer.
Fecher LA
Curr Treat Options Oncol; 2013 Jun; 14(2):237-48. PubMed ID: 23558911
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
Queirolo P; Cinquini M; Argenziano G; Bassetto F; Bossi P; Boutros A; Clemente C; de Giorgi V; Del Vecchio M; Patuzzo R; Peris K; Quaglino P; Reali A; Zalaudek I; Spagnolo F
ESMO Open; 2023 Dec; 8(6):102037. PubMed ID: 37879235
[TBL] [Abstract][Full Text] [Related]
7. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
9. Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021.
Hoashi T; Ishikawa M; Uehara J; Oashi K; Maeda S; Kato J; Saruta H; Shichinohe R; Ohashi R; Nakamura Y; Koga H; Sugaya M;
J Dermatol; 2024 Apr; 51(4):e90-e105. PubMed ID: 38264942
[TBL] [Abstract][Full Text] [Related]
10. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of basal cell carcinoma.
Herms F; Basset-Seguin N
Expert Opin Emerg Drugs; 2021 Mar; 26(1):17-26. PubMed ID: 33412913
[No Abstract] [Full Text] [Related]
12. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
13. Beyond Mohs surgery and excisions: A focused review of treatment options for subtypes of basal cell carcinoma.
Altun E; Schwartzman G; Cartron AM; Khachemoune A
Dermatol Ther; 2021 Jan; 34(1):e14476. PubMed ID: 33125804
[TBL] [Abstract][Full Text] [Related]
14. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Management of Basal Cell Carcinoma.
Tanese K
Curr Treat Options Oncol; 2019 Feb; 20(2):13. PubMed ID: 30741348
[TBL] [Abstract][Full Text] [Related]
16. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
Zargari O; Azimi SZ; Geranmayeh S
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
[TBL] [Abstract][Full Text] [Related]
17. Identifying patients at risk for recurrent or advanced BCC.
Hamid O; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
19. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma.
Basset-Seguin N; Sharpe HJ; de Sauvage FJ
Mol Cancer Ther; 2015 Mar; 14(3):633-41. PubMed ID: 25585509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
